Finance

Fundamentals in Focus for Sarepta Therapeutics, Inc. (SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is an interesting stock at present. Now trading with a market value of 1.87B, the company has a mix of catalysts and obstacles that spring from the nature of its operations. In light of the many issues surrounding this company, we thought it was a good time to take a close look at the numbers in order to form a realistic perspective on the fundamental picture for this stock.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For SRPT, the company currently has 274.72 million of cash on the books, which is offset by 11.35 million in current liabilities. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 511.53 million in total assets, balanced by 82.39 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Sarepta Therapeutics, Inc. (SRPT) saw -62.35 million in free cash flow last quarter, representing a quarterly net change in cash of 152.3 million. Perhaps most importantly where cash movements are concerned, the company saw about -57.89 million in net operating cash flow.



Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 16.34 million in total revenues. That represents a quarterly year/year change in revenues of 0.00 in sequential terms, the SRPT saw sales decline by 2.01.

But what about the bottom line? After all, that’s what really matters in the end. Sarepta Therapeutics, Inc. (SRPT) is intriguing when broken down to its core data. The cost of selling goods last quarter was 1.89 million, yielding a gross basic income of 14.45 million. For shareholders, given the total diluted outstanding shares of 56.01 million, this means overall earnings per share of 1.50. Note, this compares with a consensus analyst forecast of -0.69 in earnings per share for its next fiscal quarterly report.




Is Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -1.44 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Sarepta Therapeutics, Inc..

Previous ArticleNext Article

Related Post

Reviewing the Insider Trends for Citigroup Inc. (C... Recent insider trends for Citigroup Inc. (NYSE:C) have caught the attention of investors. Patters in insider activity can help analysts formulate an o...
Should You Invest in Chevron Corporation (CVX)? A ... Recent insider trends for Chevron Corporation (NYSE:CVX) have caught the attention of investors. Insider data is useful because it can reveal what a c...
Finisar Corporation (NASDAQ:FNSR): Don’t Let... Finisar Corporation (NASDAQ:FNSR) gained 5.27% in Wednesday’s session, going up from its prior closing price of $20.88 to $21.98. The price has fallen...
Are U.S. Silica Holdings, Inc. (SLCA)’s Rece... Recent insider trends for U.S. Silica Holdings, Inc. (NYSE:SLCA) have caught the attention of investors. Insider activity is often a strong indicator ...
Should You Invest in Cisco Systems, Inc. (CSCO)? A... Recent insider trends for Cisco Systems, Inc. (NASDAQ:CSCO) have caught the attention of investors. Insider data is useful because it can reveal what ...